Australia's BlinkLab hits four-month high on positive ADHD study results

BlinkLab

05/08/2026 05:25

** Shares of Australia's BlinkLab BB1.AX rise as much as 15.6% to A$0.780, their highest level since April 21
** Stock marks strongest session in more than four months 
** The digital healthcare co says its European study on children aged 6 through 17 born with or without ADHD, has generated postive results
** Adds, study used smartphone-based assessments to collect neurobehavioural biomarkers such as blinking and facial reflexes to diagnose ADHD
** Findings support development of co's diagnostic platforms (Dx2) to include detection of ADHD in addition to Autism, BB1 says
** Stock down 10.5% YTD, including sessions' moves

 (Reporting by Shravya Marakini in Bengaluru)
 ((Shravya.Marakini@thomsonreuters.com;))